tiprankstipranks
Can-Fite BioPharma submits IND to FDA for Phase IIb trial of namodenoson
PremiumThe FlyCan-Fite BioPharma submits IND to FDA for Phase IIb trial of namodenoson
30d ago
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
PremiumCompany Announcements
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
1M ago
Can-Fite BioPharma Reports Reduced Losses in 2023
PremiumCompany Announcements
Can-Fite BioPharma Reports Reduced Losses in 2023
1M ago
Can-Fite BioPharma gets positive response from FDA to psoriasis pediatric plan
PremiumThe FlyCan-Fite BioPharma gets positive response from FDA to psoriasis pediatric plan
5M ago
Can-Fite BioPharma: Enrollment ongoing in study of Namodenoson in liver cancer
PremiumThe Fly
Can-Fite BioPharma: Enrollment ongoing in study of Namodenoson in liver cancer
5M ago
Can-Fite BioPharma reports  9month net loss $5.98M vs. net loss of $7.15M
PremiumThe Fly
Can-Fite BioPharma reports 9month net loss $5.98M vs. net loss of $7.15M
5M ago
Can-Fite BioPharma trading halted, news pending
PremiumThe FlyCan-Fite BioPharma trading halted, news pending
5M ago
Can-Fite: Complete response in patient with HCC treated with  namodenoson
PremiumThe Fly
Can-Fite: Complete response in patient with HCC treated with namodenoson
5M ago
Can-Fite BioPharma price target lowered to $18 from $34 at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma price target lowered to $18 from $34 at H.C. Wainwright
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100